Attovia Therapeutics (NASDAQ:ATTO) Announces Earnings Results, Misses Expectations By $0.02 EPS

Attovia Therapeutics (NASDAQ:ATTO) issued its quarterly earnings results on Monday. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02), Zacks reports.

Attovia Therapeutics Trading Up 4.5%

ATTO traded up $0.69 during trading on Monday, hitting $15.96. 325,446 shares of the company’s stock were exchanged, compared to its average volume of 350,522. Attovia Therapeutics has a 1 year low of $12.94 and a 1 year high of $28.00. The stock’s 50 day moving average is $18.06. The stock has a market capitalization of $728.57 million and a price-to-earnings ratio of -3.27.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ATTO shares. Citigroup started coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They set a “buy” rating and a $30.00 price objective for the company. Lifesci Capital assumed coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 target price on the stock. Wall Street Zen upgraded Attovia Therapeutics to a “sell” rating in a report on Saturday, September 19th. Morgan Stanley began coverage on Attovia Therapeutics in a research report on Monday, August 31st. They set an “overweight” rating and a $39.00 price target for the company. Finally, Weiss Ratings began coverage on Attovia Therapeutics in a research note on Monday, November 2nd. They set a “sell (e-)” rating for the company. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Attovia Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $42.20.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. The company is working to address conditions in which existing treatments may not provide adequate efficacy, durability, or convenience.

Attovia uses its proprietary antibody-engineering and drug-development capabilities to discover and advance biologic therapies designed to modulate disease-driving immune pathways.